Tafluprost Ophthalmic Solution 0.0015%: A Review in Glaucoma and Ocular Hypertension.

Abstract

Tafluprost ophthalmic solution 0.0015% preserved with benzalkonium chloride (BAK) 0.001% is available in several Asian countries, including Japan. In pivotal trials, BAK-preserved tafluprost ophthalmic solution 0.0015% lowered intraocular pressure (IOP) more effectively than placebo in Asian patients with normal-tension glaucoma and was at least as effective as latanoprost ophthalmic solution 0.005% in Asian patients with primary open-angle glaucoma or ocular hypertension. In other prospective studies in Asian patients with glaucoma or ocular hypertension, tafluprost ophthalmic solution 0.0015% was at least as effective as latanoprost ophthalmic solution 0.005% or travoprost ophthalmic solution 0.004% in terms of IOP lowering, and was considered easier to use and/or store. The efficacy of tafluprost ophthalmic solution 0.0015% was maintained in the longer term. Tafluprost ophthalmic solution 0.0015% was generally well tolerated. In conclusion, BAK-preserved tafluprost ophthalmic solution 0.0015% remains a useful option for the treatment of Asian patients with glaucoma and ocular hypertension.